Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Fredrik Tiberg

Market Cap

29.36 Billion SEK

Sector

Healthcare

Website

https://www.camurus.com

Last Update

2/22/2024, 12:00:00 PM

Description

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally.

Read More

Overview

Value

2

Growth

79

Health

57

Management

47

Analyst Opinion

54

Total

48

All Scores Out Of 100

Best Features

  • Very strong cashflow and earnings growth
  • Earnings growth has improved recently
  • Has a low level of debt
  • Low risk of bankruptcy
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Earnings are negative
  • There is a history of diluting shareholders
  • No margin of safety at their current market price
  • Disliked by Twitter users
  • Price-to-earnings ratio of 60.2 is higher than the market average (19.6x)
  • Dividend could be at risk

Market Peers

CAMX.ST

Key Figures

PE Ratio (TTM)

60.18

Margin Of Safety (DCF)

-108.26%

Revenue Growth (5 Year Average)

24.55%

Ratings Consensus

Neutral

Share Buybacks

-3.36%

Dividend Yeild (TTM)

0.00%

Valuation

Value Score

2

  • Estimated intrinsic-value of NaN undefined SEK is lower than current price ( 509.50 SEK)
  • Price-to-earnings ratio of 60.2 is higher than the market average (19.6x)
  • Free-cashflow-yeild of 2.21% is worse than the market average (4.7%)
  • Margin-of-safety of -108.26% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 468.8 SEK

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

60.18x

Free Cashflow Yeild

2.21%

PE/Earnings Growth

1.26

Price/Book

18.09x

Growth

Growth Score

79

  • 5 Year Average Revenue growth of 24.55% is higher than the market average (10.97%)
  • Revenue growth has improved this yeara
  • 5 Year Average Earnings growth of 21.56% is higher than the market average (14.48%)
  • Earnings growth has improved this year
  • 5 Year Average Cashflow growth of 19.75% is higher than the market average (12.35%)
  • Free Cashflow growth has improved this year

Revenue Growth

24.55%

Earnings Growth

21.56%

Cashflow Growth

19.75%

Health

Health Score

57

  • Low risk of bankruptcy
  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Debt repayments significantly impact cashflow

Altman Z Score

20.00

Piostroski Score

9.00

Debt/Equity

0.03x

Current Assets/Liabilities

3.19x

Free Cashflow/Total Debt

0.00x

Debt/Capital

0.04x

Dividend

Secure Dividend Score

0

  • Long term dividend payout ratio of 0.00% is considered good
  • Payout ratio (TTM) of 0.00% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of 0.00% is less than the market average (1.85%)
  • Very unsafe

Dividend Yeild

0.00%

Dividend Growth

0.00%

Payout Ratio (Earnings)

0.00%

Payout Ratio (Cashflow)

0.00%

Management

Management Score

47

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of -6.57% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -11.27% is lower than the market average (15%)

Average Buybacks/Dilution

-3.36%

Recent Buybacks/Dilution

5.83%

5 Year Price Volitility

24.69%

Return On Assets

-8.84%

Return On Capital Employed

-6.57%

Return On Equity

-11.27%

Return On Free Cashflow

N/A

Return On Investments

N/A

Social Sentiment

Social Sentiment Score

0

Twitter Sentiment

N/A

Stocktwits Sentiment

N/A

Analysts

Analyst Opinion

54

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Camurus AB (publ)

Currency

SEK

Beta

0.914638

Vol Avg

98161

Ceo

Mr. Fredrik Tiberg

Cik

Cusip

Exchange

Stockholm Stock Exchange

Full Time Employees

188

Industry

Biotechnology

Sector

Healthcare

Ipo Date

2015-12-03

Address

Ideon Science Park

City

Lund

State

Country

SE

Zip

223 70

Phone

46 4 62 86 57 30

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies